<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89552">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01939301</url>
  </required_header>
  <id_info>
    <org_study_id>Kline-1UM NO for PE</org_study_id>
    <secondary_id>1UM1HL113203-01A1</secondary_id>
    <nct_id>NCT01939301</nct_id>
  </id_info>
  <brief_title>Nitric Oxide to Treat Pulmonary Embolism</brief_title>
  <official_title>Randomized Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas, Southwestern Medical Center at Dallas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind study to treat subjects diagnosed with pulmonary embolism
      with inhaled nitrix oxide. In this clinical trial investigators will randomized patients to
      receive inhaled nitric oxide or sham (nitrogen + oxygen) for 24 hours. Patients must have a
      submassive pulmonary embolism (PE) and evidence of right ventricular (RV) heart dysfunction.
      Investigators hypothesize that the administration of inhaled NO + oxygen to patients with
      severe submassive PE will improve RV function, reduce RV strain and necrosis and improve
      dyspnea (difficulty breathing) more than sham oxygen treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RV function and viability</measure>
    <time_frame>5 days or hospital discharge (whichever occurs first)</time_frame>
    <description>RV function and viability assessed by the composite of normal RV size (&lt;42 mm in diastole) and TAPSE &gt; 16 mm and normal RIMP &lt; 0.40 using spectral Doppler or &lt; 0.55 using tissue Doppler) and normal FAC (&gt; 33%) and a serum hsTnT &lt; 14pg/mL. Missing values will be considered normal.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Inhaled Nitric Oxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled nitric oxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>oxygen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide + oxygen</intervention_name>
    <arm_group_label>Inhaled Nitric Oxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrogen + Oxygen</intervention_name>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 18

          -  Pulmonary imaging-proven PE, as interpreted by local radiologist

          -  At least one predictor of RV dysfunction:

               1. echocardiography with RV dilation or hypokinesis,

               2. estimated RVSP &gt;40mm HG,

               3. RV&gt;LV on CTPA,

               4. elevated troponin I (&gt;0.1 ng/mL) or natriuretic peptide (BNP &gt; 90 pg/mL),

               5. screening bedside cardiac ultrasound with color flow capability that shows RV
                  dysfunction,

               6. RV strain on ECG

          -  Plan to admit to a bed with telemetry capability

        Exclusion Criteria:

          -  Vasopressor support at time of enrollment

          -  Pregnancy

          -  Plan by clinical care team to use lytic or surgical embolectomy

          -  Plan by clinical team to use platelet inhibiting drugs

          -  Contraindication to anticoagulation

          -  Altered mental status such that the patient is unable to provide informed consent

          -  Inability to use a nasal cannula or face mask

          -  Comfort care measures instituted

          -  Supplemental oxygen requirements greater than can be administered via nasal cannula
             in order to maintain Sa)2 &gt; 80%

          -  Pneumothorax with decompression

          -  Serum MetHb &gt; 10%

          -  Recent use of drugs known to increase cGMP

          -  Use of nitroprusside or nitroglycerin within the last 4 hours

          -  Use of any other nitrates with in the past 24 hours

          -  Use of a fibrinolytic medicine within the past 14 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff A Kline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eskenazi Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>36216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>August 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Jeffrey Kline</investigator_full_name>
    <investigator_title>Vice Chair of Research</investigator_title>
  </responsible_party>
  <keyword>Pulmonary embolism clot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
